These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8094628)

  • 1. A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance.
    Altamura AC
    Schizophr Res; 1993 Jan; 8(3):187-98. PubMed ID: 8094628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
    Douyon R; Angrist B; Peselow E; Cooper T; Rotrosen J
    Am J Psychiatry; 1989 Feb; 146(2):231-4. PubMed ID: 2563211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
    Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L
    J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.
    Jann MW; Fidone GS; Hernandez JM; Amrung S; Davis CM
    Psychiatry Res; 1989 May; 28(2):153-9. PubMed ID: 2568651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects.
    Someya T; Muratake T; Hirokane G; Shibasaki M; Shimoda K; Takahashi S
    J Clin Psychopharmacol; 2000 Apr; 20(2):175-80. PubMed ID: 10770455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients.
    Hesslinger B; Normann C; Langosch JM; Klose P; Berger M; Walden J
    J Clin Psychopharmacol; 1999 Aug; 19(4):310-5. PubMed ID: 10440457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting.
    Darby JK; Pasta DJ; Dabiri L; Clark L; Mosbacher D
    J Clin Psychopharmacol; 1995 Oct; 15(5):334-40. PubMed ID: 8830064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroleptic effects on serine and glycine metabolism.
    Baruah S; Waziri R; Sherman A
    Biol Psychiatry; 1993 Oct; 34(8):544-50. PubMed ID: 7903868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
    Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
    J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lowest effective dose of depot neuroleptics.
    Hoencamp E; Haffmans PJ; Jansen GS
    Br J Psychiatry; 1992 Mar; 160():422-3. PubMed ID: 1348655
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of neuroleptic withdrawal on plasma prolactin: a possible marker of receptor adaptation.
    Kirkpatrick B; Buchanan RW; Maeda K; Carpenter WT; Jauch D; Tamminga CA
    Biol Psychiatry; 1989 Jun; 26(2):131-8. PubMed ID: 2567610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: relation to side effects, psychosocial function and depression.
    Gitlin MJ; Nuechterlein KH; Mintz J; Fogelson D; Bartzokis G; Ventura J; Subotnik K; Aravagiri M
    Psychopharmacology (Berl); 2000 Mar; 148(4):350-4. PubMed ID: 10928306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some biological correlates of drug resistance in schizophrenia: a multidimensional approach.
    Altamura AC; Bassetti R; Cattaneo E; Vismara S
    World J Biol Psychiatry; 2005; 6 Suppl 2():23-30. PubMed ID: 16166020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 18. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
    Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
    Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological profile of risperidone.
    Ereshefsky L; Lacombe S
    Can J Psychiatry; 1993 Sep; 38 Suppl 3():S80-8. PubMed ID: 7504573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.